- Admin
- #1
With its shares down by 4.2% in the last 12 months, Zai Lab (NASDAQ: ZLAB) is now poised to surge like wildfire. Thanks to the slew of looming launches of new products, Wall Street analysts have set some aggressive price targets for Zai Lab on average, calling for its price near $40.90 to rise by 98% to reach $81.04 within a year -- and the analysts are probably right. Before 2026, it plans to commercialize up to 11 new therapies, ranging from biologics like Adagrasib for colorectal cancer and non-small cell lung cancer to more exotic interventions, like tumor treating fields (TTFields), which is a therapy based on electromagnetic energy projected from a specialized device.